Skip to main content
Fig. 1 | BMC Gastroenterology

Fig. 1

From: Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution

Fig. 1

Study selection and flow-chart of UC patients’ 1-year follow-up. a Follow-up scheme protocol performed in active UC patients receiving conventional therapy (baseline). Responder UC patients completed the entire follow-up period. Non-responder patients re-started the follow-up with biological therapy and were examined at 1 month, 14 weeks, 6 and 12 months. Clinical subscore, FC and serum sST2 were evaluated at 1, 3, 6 and 12 months. Endoscopic subscore and intestinal ST2 were determined at baseline, 14 weeks (w) and 6 months. b Flow-chart of patients enrolled in the follow-up

Back to article page